Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,932Revenue $M16,671Net Margin (%)14.8Z-Score3.2
Enterprise Value $M43,942EPS $4.6Operating Margin %17.2F-Score6
P/E(ttm))15.6Cash Flow Per Share $5.6Pre-tax Margin (%)15.1Higher ROA y-yY
Price/Book4.610-y EBITDA Growth Rate %10.9Quick Ratio1.1Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %5.5Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %3.7ROA % (ttm)9.8Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)29.5Less Shares Outstanding y-yY
Payout Ratio %58.0Shares Outstanding M543ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXRichard Pzena 2014-12-31 Buy 1.5%$67.24 - $74.7
($71.71)
$ 69.91-3%New holding3,944,140
BAXBill Nygren 2014-12-31 Sold Out -0.75%$67.24 - $74.7
($71.74)
$ 69.91-3%Sold Out0
BAXJean-Marie Eveillard 2014-12-31 Reduce-0.06%$67.24 - $74.7
($71.71)
$ 69.91-3%Reduce -32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$67.24 - $74.7
($71.71)
$ 69.91-3%Reduce -23.14%172,900
BAXJoel Greenblatt 2014-12-31 Buy $67.24 - $74.7
($71.74)
$ 69.91-3%New holding5,186
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 69.91-7%Sold Out0
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 69.91-7%New holding3,397
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 69.91-5%Add 90872.40%1,000,696
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 69.91-5%Sold Out0
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 69.91-5%New holding37,150
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 69.91-5%Sold Out0
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 69.912%Reduce -77.96%531,100
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 69.912%New holding204,560
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 69.912%New holding2,453
BAXChris Davis 2014-03-31 Sold Out $66.49 - $72.85
($68.77)
$ 69.912%Sold Out0
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 69.912%Reduce -85.53%1,100
BAXJean-Marie Eveillard 2013-12-31 Reduce-0.26%$63.89 - $69.47
($66.75)
$ 69.915%Reduce -99.44%7,600
BAXJames Barrow 2013-12-31 Sold Out -0.22%$63.89 - $69.47
($66.75)
$ 69.915%Sold Out0
BAXVanguard Health Care Fund 2013-12-31 Reduce-0.17%$63.89 - $69.47
($66.75)
$ 69.915%Reduce -24.20%2,410,000
BAXRobert Olstein 2013-12-31 Add0.15%$63.89 - $69.47
($66.75)
$ 69.915%Add 24.19%77,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-2.03view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-6.72view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-9.24view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-9.05view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-8.07view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-6.1view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-7.19view
STROUCKEN ALBERT P LDirector 2014-04-24Buy696$67.523.48view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-3.56view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-4.44view

Press Releases about BAX :

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Live Off Your Monthly Dividend Portfolio Mar 19 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Best Stock Pick For Long Term Investors Feb 10 2015 
Richard Pzena's New Buys Feb 09 2015 
Richard Pzena's 5 New Q4 Stock Buys Feb 07 2015 
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 


More From Other Websites
Final Glance: Pharmaceuticals companies Apr 13 2015
Final Glance: Pharmaceuticals companies Apr 13 2015
Final Glance: Medical Devices companies Apr 13 2015
Final Glance: Medical Devices companies Apr 13 2015
Midday Glance: Medical Devices companies Apr 13 2015
Midday Glance: Medical Devices companies Apr 13 2015
Midday Glance: Pharmaceuticals companies Apr 13 2015
Midday Glance: Pharmaceuticals companies Apr 13 2015
Early Glance: Medical Devices companies Apr 13 2015
Early Glance: Pharmaceuticals companies Apr 13 2015
Early Glance: Pharmaceuticals companies Apr 13 2015
Early Glance: Medical Devices companies Apr 13 2015
Baxter International First Quarter 2015 Financial Results Conference Call Apr 07 2015
Baxter International First Quarter 2015 Financial Results Conference Call Apr 07 2015
Baxter Partners Aguettant for Trace Elements in PN Therapy - Analyst Blog Apr 06 2015
BioMed scores against rival Alexandria with new lease to Biogen Apr 02 2015
Baxter's HOMECHOICE CLARIA APD System Gets CE Mark - Analyst Blog Apr 02 2015
These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter Apr 02 2015
Baxter and Laboratoire Aguettant Announce Global Collaboration for Parenteral Nutrition Trace... Apr 02 2015
Baxter and Laboratoire Aguettant Announce Global Collaboration for Parenteral Nutrition Trace... Apr 02 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 9 months ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK